
QoN 020-01

Have you or your organisation ever received direct or indirect support from the Pharmaceutical industry, including research grants, sponsorships, attendance at conferences or events, including from manufacturers of pharmacotherapies such as, but not limited to, Johnson & Johnson, Pfizer and GlaxoSmithKline?

Response: I have already answered that question which was put to me by Senator Hughes when I gave evidence on 19 November, 2020.

I will answer again.

Between 2000-2001 –19-20 years ago. I was a member of Australian Smoking Cessation Research Consortium (R Borland, S Chapman, K Jamrozik, L Roberts, C Silagy). Funding was provided by GlaxoSmithKline to pay for a national survey of smokers and ex-smokers. This resulted in: Oakes W, Chapman S, Balmford J, Borland R, Trotter L. “Bulletproof skeptics in life’s jungle”: which self-exempting beliefs about smoking most predict lack of intention to quit? [Prev Med](#) 2004;39:776–82. No funding was made to me nor my university for this. GSK directly paid the survey company’s costs.

Other than the above, I have never received any direct or indirect support for any purpose from any pharmaceutical company or agents or third parties acting on their behalf.

Senator Hughes may be unaware that I have been persistently critical of the effectiveness of nicotine replacement therapy for many years, having published many critical papers on the issue.

Simon Chapman AO PhD FASSA HonFFPH (UK)
Emeritus Professor
Sydney School of Public Health
University of Sydney AUSTRALIA